医药行业周报：本周申万医药生物指数下跌2.8%，关注全国两会政府工作报告-20260309

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook compared to the overall market performance [3][15]. Core Insights - The pharmaceutical sector experienced a decline of 2.8% this week, underperforming against the Shanghai Composite Index, which fell by 0.93% [3][4]. - The biopharmaceutical industry has been designated as a "new pillar industry" in the national government work report, signaling strong policy support for its development [3][15]. - Recent trends show an increase in the prices of bulk raw materials, suggesting potential investment opportunities in companies like Xinhecheng, Zhejiang Pharmaceutical, and Tianxin Pharmaceutical [3][23]. Market Performance - The pharmaceutical index ranked 17th among 31 sub-industries, with various segments showing mixed performance: raw materials (-3.4%), chemical preparations (-1.7%), and medical devices (-4.6%) [3][4][7]. - The overall valuation of the pharmaceutical sector stands at 30.5 times earnings, ranking 12th among 31 primary industries [3][7]. Recent Key Events Government Policy - The government work report explicitly includes biopharmaceuticals as a key industry, alongside integrated circuits and aerospace, marking a significant policy shift [3][15]. - In 2025, China is expected to approve 76 innovative drugs, with domestic innovations accounting for a substantial portion of new approvals [15]. Collaboration and Licensing - Deqi Pharmaceuticals entered a global exclusive licensing agreement with U.S.-based company for a T-cell engaging antibody, with a total transaction value exceeding $1.18 billion [16]. - Shouyao Holdings has adjusted its collaboration model for a JAK2 inhibitor, streamlining ownership and payment structures [18]. New Drug Development - Avidity reported promising clinical data for a muscle-targeting antibody-drug conjugate, showing significant efficacy in reducing mRNA levels in patients [19]. - The first patient has been dosed with a novel dual-target siRNA drug developed by Beibeite, marking its entry into clinical trials [20]. - The first patient has also been dosed with RTX-117, the first "AI+RNA" small molecule drug in China, developed by Jintai Technology [20]. Financing Activities - Aidi Pharmaceuticals plans to raise up to 1.277 billion RMB, focusing on global clinical development for an HIV integrase inhibitor [23]. Investment Recommendations - Investors are advised to monitor companies involved in raw material production and innovative drug development, including Heng Rui Medicine, BeiGene, and Aidi Pharmaceuticals [3][23].